A Ph 1 Study of Epanova® in Healthy Chineses

Study identifier:D5881C00001

ClinicalTrials.gov identifier:NCT03574142

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Open-label Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Epanova® in Chinese Healthy Subjects Living in China

Medical condition

Healthy subjects

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Epanova

Sex

All

Actual Enrollment

14

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 04 Jun 2018
Primary Completion Date: 27 Jun 2018
Study Completion Date: 27 Jun 2018

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Basic Science

Verification:

Verified 01 Feb 2019 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria